4-n-myristoyl-gemcitabine

4-n-myristoyl-gemcitabine is a **lipid-conjugated prodrug of gemcitabine**, in which a myristoyl (tetradecanoyl) group is covalently attached at the N4 position of the cytidine ring in gemcitabine. This chemical modification is designed to enhance the pharmacokinetic profile of gemcitabine, improve membrane permeability, and potentially bypass certain resistance mechanisms. As with other lipid-conjugated prodrugs, the compound is expected to be metabolized in vivo to release active gemcitabine, which is a nucleoside analog that inhibits DNA synthesis and induces cell death in rapidly dividing tumor cells. The agent is under **preclinical or early clinical development** and is not an approved therapeutic. The mechanism of action, following conversion to gemcitabine, involves incorporation into DNA of replicating tumor cells, leading to masked chain termination and apoptosis.

Other names

N4-myristoyl-gemcitabineN-4-myristoyl-gemcitabineN 4-myristoyl-gemcitabine